There were 811 press releases posted in the last 24 hours and 172,087 in the last 365 days.

2017 TOP PENNY STOCK MYDX GETS RAMPED UP AND ENTERS INTO MAJOR LICENSING DEAL

BlackSwan enters the Delivery Pen and Supplements Markets with I+huntr Brand, Tailored for Performance Athletes, Powered by MyDx360

MYDX (OTCQB:MYDX)

SAN DIEGO , CALIFORNIA, UNITED STATES, June 19, 2017 /EINPresswire.com/ -- MyDx Enters Into An ~$80,000 MyDx360
SaaS Licensing And Services Agreement
With Retailer BlackSwan
BlackSwan enters the Delivery Pen and Supplements Markets with
I+huntr Brand, Tailored for Performance Athletes, Powered by
MyDx360
-MyDx, Inc. (OTCQB: MYDX), a science and
technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld
chemical analyzer designed for cannabis professionals and retail consumers to correlate
the chemical profile of cannabis with how it makes them feel and which ailments they
report it alleviates, today announced a definitive agreement with BlackSwan, a developer
and retailer of custom vaporizers, to provide a community engagement software platform
to support its new product development initiatives under the terms of MyDx360.
Licensing Agreement Provides for Branding on Multiple Delivery Mechanisms
As part of the MyDx360 agreement, BlackSwan chose from one of MyDx's base chemical
formulations that best alleviated pain and inflammation according to the MyDx community.
From there, MyDx software enabled BlackSwan to "boost" that formula by changing
various cannabinoid and terpene parameters as well as other natural organic terpenes to
come to a final formula uniquely formulated by BlackSwan.
"This uniquely positions MyDx at the center of a revolution in how therapies are developed
utilizing chemicals found in cannabis and other naturally occurring plants. The MyDx360
platform makes it incredibly easy for market players to create new high-quality tailored
formulations that can support their customer's needs. It also speaks to our ability as a
company to execute on our vision of creating a brand-centric ecosystem powered by
community-driven data. We look forward to supporting BlackSwan and the development
of the I+huntr brand personalized for high-performance athletes and powered by
MyDx360," said Daniel Yazbeck, CEO of MyDx.
MyDx will continue to work with BlackSwan to support the development of new
formulations, which will be manufactured in the form of concentrates via state-licensed
suppliers, and then delivered via MyDx's hardware, the ECO Smart Pen, and supplements
tailored to performance athletes. Once products have been delivered via MyDx's
manufacturing partnerships, the MyDx App will provide customer-engagement support to
acquire and analyze user feedback.
BlackSwan to Launch I+huntr Brand for High Performance Athletes
BlackSwan intends to market its unique formula under theI+huntr Brand to athletes
seeking alternatives to traditional opioid pain killers, among other ailments – an area the
company has significantly researched and thinks will grow into a substantial market,
especially as cannabinoid and other natural plant extract therapeutic use becomes more
widely accepted.
"We see this as an opportunity to develop a quality product and reduce the time to market
for the Delivery Pen and Supplement markets with targeted formulas we can brand and
sell," said BlackSwan CEO, Jeff Lau. "Moreover, we think there's significant opportunity in
this space to differentiate, capture market share and truly offer products that might help
alleviate specific ailments or side effects as defined by cannabis users and we're excited
to be working with the foremost authority on the subject in MyDx."
BlackSwan intends to have its products available for sale by January of 2018 with an initial
launch in the State of California, which represents close to 50% of the US cannabis
market. The company will offer its products in three distinct organic flavors (Orange Crush,
Blueberry and Mint), which will target various levels of recovery based upon cannabis user
formulas addressing their anxiety, pain management, recovery, and performance.
Cannabis Offers the Potential to Curb the Opioid Crisis Among Athletes
Addiction to pain killers is Youth Athletics' dirty little secret as young men and women vie
for prestigious college athletic scholarships and eventually elite status as professionals.
The abuse is well documented among athletes; however, little to no alternatives have
been provided that have the dual potential of alleviating their addictions as well as
providing inflammation and pain relief.
In an article by Sports Illustrated titled "How painkillers are turning young athletes into
heroin addicts", SI covered the tragic story of Roman Montano, a high school baseball
Phenom who was destined to be a star and, at one time, started over current Phillies Ace,
Ken Giles. Unfortunately, that story would never came true. A foot injury would lead to an
OxyContin addiction that would eventually transform him into a heroin addiction. That
heroin addiction would end that young man's life at a tender age of 22.
Unfortunately, we'll never know what might have been had Roman remained healthy, and
it's a story that hasn't been lost on BlackSwan CEO Jeff Lau.
"This is a topic that many people aren't talking about because it's a bit taboo, there's big
money involved and there's immense pressure to perform when injured," said BlackSwan
CEO, Jeff Lau. "Fortunately, the chemicals in cannabis have shown tremendous promise
in its ability to alleviate pain and inflammation in much of the same way as opioids, but
without the propensity for addiction, and with the potential for additional health benefits,
which are still undergoing studies."
The reality is that since cannabis is still a Scheduled I drug federally, many people who
would otherwise have alternatives to opioids can't get them. Moreover, if they decided to
use cannabis as an alternative, then they could potentially violate substance abuse
policies that currently exist in all levels of athletics and that could have severe
consequences, financial or otherwise.
The good news is that formulating cannabis with ingredients that have healing factors
without the "high" associated with cannabis (namely CBD and various Terpenes) is
gaining wider acceptance and could potentially one day be the drawing line that many
athletes have hoped for. This is exactly the area BlackSwan intends to focus on with the
help of MyDx.
CBD and Terpene Formulations Have Demonstrated Anti-Inflammation Properties
CBD has been reported by various publications and research reports to be a cannabinoid
known for its extensive therapeutic value. It is a powerful anti-epileptic, anti-depressant,
anti-inflammatory, anti-nauseate, sleep aid, muscle relaxant, sedative and antiproliferative.
Some people call it the "Miracle Drug." What makes it popular among users is
its non-psychotropic properties, meaning it does not give you the "high" that you feel when
you consume THC. As a result, it can also be administered at relatively high doses without
any known undesired psychological side effects.
Terpenes are naturally occurring compounds that give plants and flowers their unique
smell. In cannabis plants, terpenes originate from the same glands that produce THC,
CBD and other cannabinoids and assist the effects of cannabinoids by also interacting
with endocannabinoid system in people, otherwise known as the "Entourage Effect."
Terpenes with anti-inflammatory and pain reducing properties include Caryophyllene,
Linalool, and Pinene, to name a few.
To learn more about the cannabinoids, terpenes, the entourage effect, and the science of
how they all interact to impact our physiology, please refer to Part 3: Cannabis 2.0 on
page 17 of the MyDx White Paper.
About MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor technology company
based in San Diego, California whose mission is to help people Trust & Verify® what they
put into their minds and bodies. The Company developed MyDx®, a patented, affordable
portable analyzer that provides real-time chemical analysis and fits in the palm of the
user's hand. The multi-use MyDx Analyzer leverages over a decade of established
chemical detection technology to measure chemicals of interest. The Company owns a
substantial and growing intellectual property portfolio of patents covering its technology.
The MyDx AquaDx®, OrganaDx
(TM) and CannaDx
(TM) sensors are now commercialized,
and the AeroDx® application is next in line. All sensors will be compatible with a MyDx
App that empowers consumers to live a healthier life by revealing the chemical
composition of what they eat, drink and inhale. For more information, please
visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section
27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities
Exchange Act of 1934, as amended. Statements may contain certain forward-looking
statements pertaining to future anticipated or projected plans, performance and
developments, as well as other statements relating to future operations and results. Any
statements in this press release that are not statements of historical fact may be
considered to be forward-looking statements. Words such as "may," "will," "expect,"
"believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or
variations of these or similar words, identify forward-looking statements. These forward-looking
statements by their nature are estimates of future results only and involve
substantial risks and uncertainties, including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements, development of
new products, our ability to complete our product testing and launch our product
commercially, the acceptance of our product in the marketplace, the uncertainty of the
laws and regulations relating to cannabis, the impact of competitive products or pricing,
technological changes, the effect of economic conditions and other uncertainties detailed
from time to time in our reports filed with the Securities and Exchange Commission,
available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@cdxlife.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/newsreleases/mydx-enters-into-an-80000-mydx360-saas-licensing-and-services-agreementwith-retailer-blackswan-300475524.h

Neil Gross
Pen Stock Picks
4242549715
email us here